Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin

Neoplasia

Volumn 7, Issue 7, 2005, Pages 705-713

  El Kareh, Ardith W ^a   Secomb, Timothy W ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Adriamycin; Cellular pharmacodynamics; Chemotherapy; Doxorubicin; Mathematical model

Indexed keywords

DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CELL SURVIVAL; CYTOTOXICITY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG UPTAKE; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

EID: 23244457368     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.05118     Document Type: Article

References (30)

1. Doroshow JH (1996). Anthracyclines and anthraincendiones. In Chabner BA and Longo DL, Eds. Cancer Chemotherapy and Biotherapy, 2nd Ed. Lippincott-Raven: Philadelphia, PA. p. 409-434.
2. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, and Inaba M (1988). Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 21, 185-190.
3. Eichholtz-Wirth H (1980). Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41, 886-891.
4. El-Kareh AW and Secomb TW (2003). Theoretical analyses and simulations of anticancer drug delivery. In Brown DM, ed. Drug Delivery Systems in Cancer Therapy. Humana Press: Totowa, NJ.
5. Lankelma J, Luque RF, Dekker H, and Pinedo HA (2003). Simulation model of doxorubicin activity in islets of human breast cancer cells. Biochim Biophys Acta Gen Subj 1622, 169-178.
6. Millenbaugh NJ, Wientjes MG, and Au JLS (2000). A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 45, 265-272.
7. Levasseur LM, Slocum HK, Rustum YM, and Greco WR (1998). Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58, 5749-5761.
8. Gardner SN (2000). A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Cancer Res 60, 1417-1425.
9. Gewirtz DA (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics, adriamycin and daunorubicin in the tumor cell. Biochem Pharmacol 57, 727-741.
10. Kerr DJ, Kerr AM, Freshney RI, and Kaye SB (1986). Comparative intracellular uptake of adriamycin and 4′-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival. Biochem Pharmacol 35, 2817-2823.
11. Lobo ED and Balthasar JP (2002). Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4 (4), E42.
12. El-Kareh AW and Secomb TW (2003). A mathematical model for cisplatin cellular pharmacodynamics. Neoplasia 5, 161-169.
13. Eliaz RE, Nir S, Marty C, and Szoka FC (2004). Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 64, 711-718.
14. Link KH, Leder G, Pillasch J, Butzer U, Staib L, Kornmann M, Bruckner U, and Beger HG (1998). In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol 14, 189-201.
15. Nguyen-Ngoc T, Vrignaud P, and Robert J (1984). Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors. Oncology 41, 55-60.
16. Rupniak HT, Whelan RD, and Hill BT (1983). Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int J Cancer 32, 7-12.
17. Vrignaud P, Londosgagliardi D, and Robert J (1986). Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture. Oncology 43, 60-66.
18. Walker MC, Masters JRW, Parris CN, Hepburn PJ, and English PJ (1986). Intravesical chemotherapy-in vitro studies on the relationship between dose and cytotoxicity. Urol Res 14, 137-140.
19. Maestre N, Tritton TR, Laurent G, and Jaffrezou JP (2001). Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappa B activation but not apoptosis signaling. Cancer Res 61, 2558-2561.
20. Nagasawa K, Natazuka T, Nomiyama M, Ohnishi N, and Yokoyama T (1996). Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin. Biol Pharm Bull 19, 100-105.
21. Bates DA, Fung H, and Mackillop WJ (1985). Adriamycin uptake, intracellular binding and cytotoxicity in Chinese hamster ovary cells. Cancer Lett 28, 213-221.
22. Au JLS, Li D, Gan YB, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh HJ, Chen CT, et al. (1998). Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 58, 2141-2148.
23. Fister KR and Panetta JC (2000). Optimal control applied to cell-cycle-specific cancer chemotherapy. Siam J Appl Math 60, 1059-1072.
24. Iliadis A and Barbolosi D (2000). Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput Biomed Res 33, 211-226.
25. Martin RB, Fisher ME, Minchin RF, and Teo KL (1990). A mathematical model of cancer chemotherapy with an optimal selection of parameters. Math Biosci 99, 205-230.
26. Neale MH, Lamont A, and Cree IA (2000). The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma. Br J Cancer 83, 80.
27. Lippman ME (2000). High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. New Engl J Med 342, 1119-1120.
28. Phillips RM and Clayton MRK (1997). Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. Br J Cancer 75, 196-201.
29. Wilson RE, Keng PC, and Sutherland RM (1989). Drug-resistance in Chinese-hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 81, 1235-1240.
30. Walker J, Martin C, and Callaghan R (2004). Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40, 594-605.